Brandy D. Gunsolus, DCLS, MLS(ASCP)CM, describes the manifestation of systemic mastocytosis in individuals based on skin tone and gender. Dr Gunsolus also provides insights for helping to ensure that patients receive an accurate diagnosis.
In an interview conducted at the 2024 American Society of Hematology Annual Meeting in San Diego, California, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center,…
In an interview conducted at the 2024 Congress of the European Hematology Association in Madrid, Spain, Lindsay Rein, MD, Duke University Medical Center, Durham, North Carolina, provided insights…
In an expert roundtable discussion, Matthew P. Giannetti, MD, Harvard Medical School, Brigham and Women’s Hospital Mastocytosis Center, Boston, Massachusetts; Lauren M. Madigan, MD, University of Utah, University…
John M. Fahrenholz, MD, Vanderbilt University Medical Center, Nashville, Tennessee, discusses questions about nonadvanced systemic mastocytosis submitted by participants. Topics include triggers for mast cell activation, management strategies…
Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
